Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Payables: 2019-2024

Historic Payables for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $1.3 million.

  • C4 Therapeutics' Payables fell 11.37% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year increase of 1.22%. This contributed to the annual value of $1.3 million for FY2024, which is 8.16% down from last year.
  • As of FY2024, C4 Therapeutics' Payables stood at $1.3 million, which was down 8.16% from $1.4 million recorded in FY2023.
  • C4 Therapeutics' 5-year Payables high stood at $5.7 million for FY2020, and its period low was $1.2 million during FY2022.
  • In the last 3 years, C4 Therapeutics' Payables had a median value of $1.3 million in 2024 and averaged $1.3 million.
  • Its Payables has fluctuated over the past 5 years, first crashed by 73.99% in 2022, then climbed by 23.38% in 2023.
  • Yearly analysis of 5 years shows C4 Therapeutics' Payables stood at $5.7 million in 2020, then dropped by 20.71% to $4.5 million in 2021, then crashed by 73.99% to $1.2 million in 2022, then climbed by 23.38% to $1.4 million in 2023, then declined by 8.16% to $1.3 million in 2024.